

A Review On Diabetes Mellitus

Shirish Raut¹ , Suhas Tiwaskar² , Roshan Umate³

1. B.Sc MLT INTERN, Department of Pathology, School of Allied Health Sciences, Datta Meghe Institute Of Medical Sciences
2. Assistant Professor, MRIT (Medical Radiology and Imaging Technology), Department of Radiology, School of Allied Health Sciences, Datta Meghe Institute of Medical Sciences, Wardha, Maharashtra, India
3. Research Scientist, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha, Maharashtra.

DOI: 10.47750/pnr.2022.13.S08.26

Abstract

Diabetes, often known as diabetes mellitus, is a group of metabolic diseases in which a human's blood sugar levels are uncontrollably high because either the body produces insufficient insulin or the cells aren't producing enough insulin to work properly. The traditional signs of polydipsia (increased thirst), and polyphagia, polyuria (frequent urine) are caused by this elevated blood sugar level (increased hunger). According to conventional wisdom, diabetes is divided into 3 types: Type 1 Diabetes Mellitus is unable to secrete insulin and the patient must currently administer insulin intravenously or use an insulin pump. It is also referred to as 'juvenile diabetes.' Insulin resistance is the root cause of type two diabetes mellitus. A disease in which cells are unable to adequately utilize insulin, whether or not they are also completely insulin deficient. Previously, this variety was known as "adult-onset diabetes." Gestational diabetes, When a pregnant woman who has never had diabetes develops excessive blood sugar levels, the third major form of the disease is triggered. It might happen before type 2 Diabetes Mellitus develops Right now accessible pharmacotherapies for Diabetes Mellitus incorporate insulin and oral hypoglycemic drugs. These medications either increment pancreatic insulin union or decrease glucose levels through expanding glucose take-up while diminishing gluconeogenesis. However, these present medications do not prolong the restoration of normal glucose homeostasis and they do not come without adverse effects including They must live the remainder of their life with, kidney disorders, GIT issues, hepatotoxicity, heart risk issues, hypoglycemia, insulinoma, and other conditions. Due to the therapeutic ingredients in various herbal medicines, they have also been proven successful in the treat of diabetes. Therefore, the current review makes an effort to concentrate on the physiologically features of diabetes, management objectives, conveniences, and synthetic diabetes therapy using herbs.

INTRODUCTION

The very common endocrine disease, diabetes mellitus affects more than 10 crores separately and globally (6.0% of the human population). It is brought on by the pancreas' insufficient or insufficient secretion of enzyme insulin, which causes a spike and decrease in blood glucose level. Numerous biological systems including blood vessels, The skin, The eyes, the heart, kidneys, feet have been discovered to be damaged by it (1). IDDM Type 1 and NIDDM, Type 2 are the two categories into which diabetes mellitus has been divided). In contrast to Type two diabetes, this is defined as peripheral insulin resistance, less insulin secretion, An autoimmune disease known as type one diabetes is characterized by an islet-specific inflammation response and the selective death of insulin-secreting cells. (2)The risk of several consequences, including renal failure, CVD, peripheral disease, neuropathy, retinopathy, amputation, stroke, and blind, is raised when diabetes mellitus (DM) is present (3)The main purposes of drugs are to treat symptoms and extend life. Additional objectives include preventing long-term diabetes issues and lengthening lifespan by reducing risk factors.reguler Life and diet changes are regarded as the cornerstone for the treatment and maintenance of type 2 DM, insulin replaces individuals with type 1 DM (4)Biguanides and sulfonylureas are just a couple of the different kinds of hypoglycemic medications that can be used to treat diabetes. However, due to their harmful side effects and occasionally seen responses decrease with continued usage, none of these drugs are optimal (5)The primary drawback of current Reddy medications is that's why must

be used continuously throughout life and result in adverse effects (6) Bioactive components and medicinal herbs and their bioactive components can be utilized to treat diabetes mellitus all over the world, especially in places where access to the standard anti-DM medications is insufficient (3) There are also numerous experimental models available to test a plant's antidiabetic potential (7) To gain a more detailed understanding of diabetes mellitus, including its clinical manifestation, epidemiology statistics, complicated, and current availability treatments, the current review's objective is to provide such information.

Epidemiology

In 2011, 36.6 crores separately were supposed to have diabetes mellitus by 2031, this Nu will have raised to 55.2 crores. Type 2 diabetes is turning out to be more normal around the world, with 81% of people impacted living in low-and center pay nations. In 2011, 0.46 crore individuals died from DM. By 2031, 43.9 crore people are anticipated to foster sort 2 diabetes. Due to ecological and way of life risk factors, the frequency of type 2 diabetes altogether shifts with geographic location(9). The predominance of diabetes in grown-ups, explicitly type 2 DM, is anticipated to increment over the course of the following 20 years, with a lot of that rising in arising countries, where patients are generally between the ages of 45 and 64. (10).

Diabetes in India

Recent estimates show that 28.5 crore people globally (6.6%) are between the ages of 20 and 79. In 2010, the group will have diabetes, and by 2030, 43.8 crore adults (7.8%) are predicted to have the disease. India holds the unenviable title having the highest proportion of diabetic subjects in the globe. if no immediate preventive action is done, the country of India's estimated 4.09 crore diabetics may increase to 6.99 crores by 2025. In urban populations, changes in eating habits and a decline in physical activity can lead to higher prevalences of diabetes mellitus(11) Given that there are already 6.2 crore diabetics in India, the disease is quickly reach the status of a possible epidemic (12-13) India (3.17 crore) had the most persons worldwide with diabetes mellitus in 2000, followed by China (2.08 crore) and the United States (1.77 crores), which came in 2nd and 3rd, respectively From 17.1 billion in 2000 to 36.6 billion in 2031, the no of separately with diabetes is predicted to treble, with India seeing the highest growth. In India, the no of people with diabetes mellitus is expected to reach 7.94 crores by 2031, while the number of people with the condition in China (4.23 crore) and the United States (3.03 crore) is also expected to rise significantly (10-14)

Pathophysiological aspects are

Because of insulin resistance, less insulin production, and ultimately failing pancreatic B cells, type 2 diabetes is characterized by insulin insensitivity. Less glucose is consequently delivered to the liver, muscles, and fat cells. Increased fat breakdown occurs when blood sugar levels are elevated (15-16). Patients with type 1 diabetes who initially experience symptoms are typically young (children or teenagers) and not obese. 1st° relatives of an index case have a 10-fold higher incidence of the condition, and specific histocompatibility antigens (HLA) types are strongly associated with it. Identical twin studies have demonstrated that those who are genetically susceptible must additionally be exposed to an environmental component, viral infection may harm pancreatic B cells and expose antigens that trigger an autoimmune reaction that keeps happening on its own. When more than 90% of the B cells are eliminated, the patient only reveals overt diabetes. In this type, low insulin levels weaken long-term potentiation and may result in learning and memory problems. Insulin resistance and reduced insulin secretion, The prevalence of these patients, who are frequently obese and typically present in adulthood as B-cell activity declines, increases with time. In this case, tau hyperphosphorylation and A plaque development are both caused by insulin resistance. Insulin and A compete for the insulin-degrading enzyme during hyperinsulinemia, which causes A buildup and plaque development. Reduced insulin receptor signaling occurs in tau hyperphosphorylation, Akt inhibition, and GSK-3 dephosphorylation (activation) (17- 18).

Complications

As the disease gets worse, vascular or tissue damage takes place, which can result in serious diabetic side effects such as ulceration, neuropathy, and kidney problem Patients with type 1 DM who have had it for quite a while are more inclined to microvascular issues as well as macrovascular infection (heart, fringe vascular, and coronary corridor diseases)(19-20). Enormous vessel atherosclerosis in type 2 diabetes is exceptionally unsafe and every

now and again joined by weight, hyperlipidemia, hypertension, End-stage renal illness and cardiovascular issues are the main sources of death in type 2 diabetes patients (4)

Diagnosis

Although PMBS, FBS are also used for blood sugar measurement and American Diabetes Association recommends using the fasting glucose concentration for regular diabetes screening. At least one of the following criteria must be met in order to diagnose diabetes:

Diabetic symptoms (urinate, thirsty, weight loss, fatigue, etc.) and a routine glucose level of 200 mg/dL were both present

The normal range of 70-110 mg/dl for fasting plasma glucose should be achieved after at least 7 to 8 hours without consuming any calories.

Like the ADA, the WHO grouping incorporates both the clinical phases of diabetes mellitus (normoglycemia, weakened glucose resilience/disabled fasting glucose (IGT/IFG), and diabetes as well as the etiological sorts of the illness. Be that as it may, Fasting glucose = 125 mg/dL and/or GDM, previously known as gestational debilitated glucose resilience (GIGT), are remembered for the WHO group(4).

Goals of management

The fundamental goal of primary prevention is to stop diabetes from developing in vulnerable people or the general community. Regular physical activity is crucial for both managing and preventing diabetes. Increased physical activity has been proven to have a protective impact against the onset of type two diabetes, regardless of other risk factors, according to prospective cohort studies (21- 23) The primary goals of dietary and way of life changes are to work on the glycemic control, less the gamble coronary illness (CHD), It is prevalent in patients with type two diabetes who are overweight and also have additional metabolic conditions associated with the insulin resistance syndrome (24), and is responsible for 70% to 80% of deaths among those with diabetes. While diet and life changes are regarded as the foundation for the treatment and conservation of type two DM, insulin relief remedy is the dependence for individualities with type one DM. When diet, weight loss, exercise, and oral specifics are unfit to regulate blood glucose situations in people with type two diabetes, insulin becomes pivotal. Treatment for type two DM can potentially profit from the use of oral hypoglycemic specifics. thiazolidinediones, nascence glucosidase impediments, biguanides and Sulfonylureas are exemplifications of oral hypoglycemic drugs. Their major ideal is to correct common metabolic diseases like insulin resistance and inadequate pancreatic insulin products. Weight loss, better glucose control, and a reduced threat of cardiovascular problems, which beget 70 to 80 of losses among diabetics, are all pretensions of diet and life changes (25).

Treatment

Oral hypoglycemic medications and insulin

The goal of insulin therapy should be to replicate nature, which is very effective at preventing between-meal hypoglycemia and minimising postprandial hyperglycemia (26). For better and safer insulin action, the site of injection matters just as much. Injections can be given intravenously or intramuscularly. There are various insulin formulations available, including human, beef, and hog insulin. The use of insulin is not without risks and side effects. When insulin is administered at an insufficient amount and The most prominent unfavourable effects are hypoglycemia & weight gain when meals and insulin injections are not timed correctly (27- 28). Starting insulin therapy for uncontrolled diabetes has a normal side effect of weight gain, When uncontrolled diabetes is treated with insulin, weight gain is a common side effect that is brought on by an increase in body fat and muscle mass. Additionally, less energy is lost by glycosuria, which contributes to this (29-30). Oral hypoglycemic medications include biguanides like metformin and phenformin as well as sulphonylureas like glibenclamide and glibipizide.

Sulfonylureas stimulate the secretion of insulin from pancreatic β -cells, which results in hypoglycemia. They cause potassium channels that are ATP-sensitive to close, depolarizing the cell membrane; it does this by opening voltage-gated channels, enabling calcium ions to enter and then releasing insulin granules that have already been produced. Acute sulfonylurea therapy to Patients with type two diabetes have increased pancreatic insulin release, which may lead to even higher insulin levels if hepatic insulin clearance is restricted. Initial studies showed that pancreatic function was essential for the hypoglycemic effects of sulfonylureas; Glumetza, like Fortamet, treats hyperglycemia rather than hypoglycemia (32). Even in high doses, it does not cause the pancreas to secrete insulin or result in hypoglycemia (33). It has been demonstrated that when administered orally but not intravenously, it increases peripheral glucose absorption and decreases hepatic glucose production by about 20–30%. It has also been proposed that one of the mechanisms of action is impaired intestinal glucose absorption (34–47).

Herbal Diabetes Treatment

With extended research in the space of conventional medication throughout the course of recent many years, Plant like meds have moved from the edges to the middle thanks to their ecological, natural, monetary, and general security benefits. There are numerous writing surveys in regards to hostile to diabetic homegrown cures by different scholars, however Atta-ar-audit, Rahman's which records in excess of 300 plant species perceived for their hypoglycemic characteristics, is the most instructive. According to their herbal name, country of beginning, parts utilized, and kind of dynamic specialists, this audit has classified the plants. *Momordica charantia* of the Cucurbitaceae family is one such plant (37). 21,000 plants that are utilized as meds overall are recorded by the WHO. Out of these 2500 species, In India, one hundred fifty species are utilized financially on a sizable premise. India is known as the world greenhouse and is the country that delivers the most restorative spices (38).

Conclusion

The term diabetes mellitus integrates at least one or two metabolic issues. Whenever left untreated, achieve uncommonly high gathering of a sugar called glucose in the blood. The central target of diabetes the leaders is past what many would think about conceivable, to restore starch processing to a customary state. To achieve this goal, individuals with an absence of absolute insulin require insulin replacement treatment, which is given through imbuements or tablets. Insulin resistance, strangely, can be reconsidered by dietary modifications and exercise. Various goals of diabetes the board are to thwart or treat the various intricacies that can result from the genuine disease and from its treatment. By observing the glucose level, diabetes can transform into a patient's companion and he/she can see the value in life happily.

Competing interests

The authors affirm that the publishing of this paper does not involve any conflicts of interest.

REFERENCES

1. Ismail, M.Y., Clinical evaluation of the antidiabetic activity of *Trigonella* seeds and *Aegle marmelos* Leaves, *World Appl Sci J.*, 7(10): 1231-1234 (2009)
2. Arora, S., Ojha, S.K., Vohora, D., Characterization of Streptozotocin-induced diabetes mellitus in Swiss Albino mice, *Glo J of Pharmacol.*, 3(2): 81-84 (2009)
3. Jothivel, N., Ponnusamy, S.P., Appachi, M., Antidiabetic activities of methanol leaf extract of *Costus pictus* D. Don in alloxan-induced diabetic rats, *J of health sci.*, 53(6): 655-663 (2007).
4. Bastaki, S. Review Diabetes mellitus and its treatment, *Int J Diabetes & Metabolism*, 13: 111-134 (2005)
5. Dixit, V.P. Joshi, S. Antiatherosclerotic effects of alfalfa and injection in chicks a biochemical evaluation, *Ind J of Physiol & Pharmacol.* 29: 47-50 (1985)
6. Halin, E.M., Effect of *Coccinia indica* (L.) and *Abroma Augusta* (L) on glycemia, lipid profile and indicators of end-organ damage in streptozotocin-induced diabetic rats, *Ind J of Clin Biochem.* 18:54-63 (2003)
7. Grover, N., Bafna, P.A., Rana, A.C. Diabetes and methods to induce experimental diabetes, *Inter J of pharm and biology science.* 1(4): 414-419 (2011)
8. Olokoba, A.B., Obateru, O.A., Olokoba, L.B., Type 2 Diabetes Mellitus: A Review of Current Trends, *Oman Med J.* 27(4): 269–273 (2012)
9. Zimmet, P., Alberti, K.G. Global and societal implications of the diabetes epidemic, *Shaw J Nature.* 414(6865):782-787 (2001)
10. Wild, S., Roglic, G., Green, A. Sicree, R., King, H. Global prevalence of diabetes: estimate for the year 2000 and projections for 2030. *Diabetes Care*, 127(5):1047-1053 (2004)

11. Ramachandran, R., Das, A.K. Joshi, S.R., Current status of diabetes in India and need for novel therapeutic agents, Supplement to Japi, 58: 7-9 (2010)
12. Joshi, S.R., Parikh, R.M.India - diabetes capital of the world: now heading towards hypertension. J Assoc Physicians India. 55: 323–4 (2007)
13. Kumar, A., Goel, M.K. Jain, R.B. Khanna, P., Chaudhary, V. India towards diabetes control: Key issues. Australas Med J. 6(10): 524–31 (2013)
14. Whiting, D., Guariguata, L., Weil, C., Shaw, I.D.F. Diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 94: 311–21 (2011)
15. Kahn, C.R., Banting Lecture. Insulin action, diabetogenic, and the cause of type II diabetes. Diabetes, 43(8): 1066-1084 (1994)
16. Robertson, R.P., Antagonist: diabetes and insulin resistance–philosophy, science, and the multiplier hypothesis. J Lab Clin Med 125(5): 560-564 (1995)
17. Rang, H.P., Dale M.M., Pharmacology, Sixth Edition, Churchill Livingstone. “The Endocrine Pancreas and Control of Blood Glucose, 2008, Page No. 397-409.
18. Sims-Robinson, C., Kim, B., Rosko, A. How does diabetes accelerate Alzheimer's disease pathology? Nat Rev Neurol; 6(10): 551-559 (2010)
19. Svensson, M., Eriksson, J.W. Dahlquist, G., Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 27: 955-962 (2004)
20. Sally, C.H., Aczel, S. Marte, T. Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state. Diabetologia 47: 145-146 (2004)
21. Kondhalkar, Ankita, Ranjit Ambad, Neha Bhatt, and Roshan Kumar Jha. “Determination of Clinical Utility of Novel Biochemical Markers in Osteoarthritis.” Journal of Pharmaceutical Research International, July 31, 2021, 240–45. <https://doi.org/10.9734/jpri/2021/v33i39A32166>.
22. Kondhalkar, Ankita, Ranjit Ambad, Ninad Nagrale, and Nandkishor Bankar. “Alterations in Biochemical Markers of Kidney Function of Thyroid Disorders at Vidharbha Region, India.” Journal of Pharmaceutical Research International, July 20, 2021, 236–41. <https://doi.org/10.9734/jpri/2021/v33i37B32045>.
23. Kondhalkar, Ankita, Rajan Barokar, Prajakta Warjekar, and Roshan Kumar Jha. “Study of TNF- α , IL-6 and Insulin Resistance in Type 2 Diabetes Mellitus at Vidharbha Region.” Journal of Pharmaceutical Research International, December 15, 2021, 534–39. <https://doi.org/10.9734/jpri/2021/v33i58A34149>.
24. Kotamkar, Sonali, Rakesh Kumar Jha, and Nandkishor Bankar. “A Brief Research on Cancer.” Journal of Pharmaceutical Research International, July 28, 2021, 323–29. <https://doi.org/10.9734/jpri/2021/v33i38B32130>.
25. Kothe, Amruta, Aarti Raut, and Sheetal Sakharkar. “Assess the Effectiveness of Planned Teaching on Assisting Self-Care Activities of Patients with Plaster of Paris Casts of Lower Extremities among Caregivers.” Journal of Pharmaceutical Research International, October 29, 2021, 675–81. <https://doi.org/10.9734/jpri/2021/v33i47A33060>.
26. Kumar, Chava Aravind, Chandrashekhar Mahakalkar, and Meenakshi Yeola (Pate). “Assessment of Risk Factors in the Causation & Outcomes of Diabetic Foot.” Journal of Pharmaceutical Research International, July 15, 2021, 264–70. <https://doi.org/10.9734/jpri/2021/v33i37A32008>.
27. Kumar, Mahesh, R. K. Shinde, and Reena Jaiswal. “A Protocol for Treatment of Avabahuk (Frozen Shoulder) with Agnikarma and Topical Diclofenac Sodium Gel.” Journal of Pharmaceutical Research International, June 19, 2021, 45–52. <https://doi.org/10.9734/jpri/2021/v33i32B31739>.
28. Kumar, Rohan, and Gaurav Vedprakash Mishra. “Giant Subcutaneous Lymphangioma of the Abdominal Wall in Childhood.” Pan African Medical Journal 39 (2021). <https://doi.org/10.11604/pamj.2021.39.104.30068>.
29. Kumar, Rohan, and Gaurav Vedprakash Mishra. “Sonographic Sunray Appearance of Ewing’s Sarcoma of Skull.” Pan African Medical Journal 39 (2021). <https://doi.org/10.11604/pamj.2021.39.152.30216>.
- 30.
31. Kumari, Darshana, Swity Besekar, Karishma Wadsariya, Minal Ughade, Aditya Utkhede, and Pranay Wankhede. “Relationship between Attitude and Anxiety Related to Online Learning.” Journal of Pharmaceutical Research International, November 12, 2021, 105–10. <https://doi.org/10.9734/jpri/2021/v33i49B33346>.
32. Kumbhare, Yash. “Review of Socio-Economic and Psychological Aspects of Lockdown during COVID-19 Pandemic.” Bioscience Biotechnology Research Communications 14, no. 6 (June 15, 2021): 303–9. <https://doi.org/10.21786/bbrc/14.6.64>.
33. Kurhade, Ekta, Priyanka Paul Madhu, Kumar Gaurav Chhabra, Amit Reche, Dhanashree Rathi, and Shreya Chambhare. “Evaluation of the Knowledge and Practice of N95 Respirators (3 Layered) for Preventing COVID 19 among Health Care Workers in Central India- A Coss Sectional Study.” Journal of Pharmaceutical Research International, October 22, 2021, 435–38. <https://doi.org/10.9734/jpri/2021/v33i46B32958>.
34. Kute, Vivek B., Anil K. Bhalla, Sandeep Guleria, Deepak S. Ray, Madan M. Bahadur, Ashay Shingare, Umapati Hegde, et al. “Clinical Profile and Outcome of COVID-19 in 250 Kidney Transplant Recipients: A Multicenter Cohort Study From India.” Transplantation 105, no. 4 (April 2021): 851–60. <https://doi.org/10.1097/TP.0000000000003593>.
35. Kute, VivekB, Sandeep Guleria, AnilK Bhalla, Ashish Sharma, SanjayK Agarwal, Manisha Sahay, Santosh Varughese, et al. “ISOT Consensus Statement for the Kidney Transplant Recipient and Living Donor with a Previous Diagnosis of COVID-19.” Indian Journal of Transplantation 15, no. 2 (2021): 131. https://doi.org/10.4103/ijot.ijot_26_21.
36. Lahole, Swapnil, Sourya Acharya, Nitin Raisinghani, Sunil Kumar, and Aishwarya Ghule. “Para Infectious Guillain–Barre Syndrome (GBS) in Covid-19 – A Case Report.” Journal of Evolution of Medical and Dental Sciences 10, no. 9 (March 1, 2021): 659–61. <https://doi.org/10.14260/jemds/2021/141>.
37. Lakhwani, Madhu, and Pratik Phansopkar. “Efficacy of Percussive Massage versus Calf Stretching on Pain, Range of Motion, Muscle Strength and Functional Outcomes in Patients with Plantar Fasciitis – A Research Protocol.” Journal of Pharmaceutical Research International, September 27, 2021, 532–39. <https://doi.org/10.9734/jpri/2021/v33i44B32705>.

38. Lalawmpuii, A., and Vaishali Taksande. "To Assess the Effectiveness of Planned Teaching on Knowledge Regarding Mid-Wife Led Continuity of Care Model (MLCC) on Final Year Nursing Students." *Journal of Pharmaceutical Research International*, December 16, 2021, 508–16. <https://doi.org/10.9734/jpri/2021/v33i58B34231>.
39. Lalawmpuii, A., and Vaishali Taksande. "To Assess the Effectiveness of Self-Instructional Module on Knowledge Regarding Obstetric Danger Signs, Birth Preparedness and Complications Readiness among the Primigravida Mothers." *Journal of Pharmaceutical Research International*, October 6, 2021, 202–6. <https://doi.org/10.9734/jpri/2021/v33i45B32797>.
40. Lalawmpuii, A., Vaishali Taksande, and Manjusha Mahakarkar. "Grade IV Utero Vaginal Prolapse (Procidentia): A Case Report." *Journal of Pharmaceutical Research International*, November 11, 2021, 187–91. <https://doi.org/10.9734/jpri/2021/v33i49A33319>.
41. Lalduhawma, James, Kumar Gaurav Chhabra, Amit Reche, Priyanka Paul Madhu, . Lalruatzela, and Jonathan Lalnunsanga. "Co-Relation of Steroids in Diabetic and COVID-19 Patients." *Journal of Pharmaceutical Research International*, October 19, 2021, 128–35. <https://doi.org/10.9734/jpri/2021/v33i46B32924>.
42. Lalhriatpuii, ., and Manjusha Mahakarkar. "To Assess the Effectiveness of Patterned Breathing Technique in Reduction of Pain during First Stage of Labour among Primigravida Mothers." *Journal of Pharmaceutical Research International*, October 6, 2021, 221–24. <https://doi.org/10.9734/jpri/2021/v33i45B32799>.
43. Lalhriatpuii, ., and Bali Thool. "Comparative Assessment of Placental Weight and Fetal Outcome in Normal and Anaemic Mothers during Intranatal Period in Selected Hospitals in India." *Journal of Pharmaceutical Research International*, December 11, 2021, 72–80. <https://doi.org/10.9734/jpri/2021/v33i54B33767>.
44. Lalwani, Shivani, Shruti Deshpande, and Tasneem Burhani. "Impact of Physical Therapy in Patients Undergoing Modified Radical Mastectomy: A Case Report." *Journal of Pharmaceutical Research International*, July 15, 2021, 302–10. <https://doi.org/10.9734/jpri/2021/v33i37A32012>.
45. Lalwani, Shivani S., G. D. Vishnu Vardhan, and Ashish Bele. "Comparison the Impact on TENS and Conventional Physiotherapy in Stroke Patients with Upper Limb Dysfunctions: A Research Protocol." *Journal of Pharmaceutical Research International*, October 2, 2021, 466–75. <https://doi.org/10.9734/jpri/2021/v33i45A32767>.
46. Lalzampuii, ., and Archana Maurya. "Comparison of Selected Distraction Techniques to Alter Pain Responses among Children Receiving Immunization." *Journal of Pharmaceutical Research International*, September 17, 2021, 75–82. <https://doi.org/10.9734/jpri/2021/v33i44A32592>.
47. Larokar, Anuska. "Medical Infrastructure and Not Medical Insurance Should Be the Focal Point to Tackle Pandemic in Developing Countries Like India: A Study." *Bioscience Biotechnology Research Communications* 14, no. 6 (June 15, 2021): 271–74. <https://doi.org/10.21786/bbrc/14.6.57>.